Secukinumab, an anti IL-17 monoclonal antibody, does represent a therapeutical choice for tthe treatment of moderate-sevre psoriasis. Drug survival of Secukinumab is not as low as initially reported . Our study ndicates that the durability of Secukinumab therapy in trating psoriasis patients in the real world setting, with relative lower drug survival in biologic-experienced obese patients.
Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study / Torres T.; Balato A.; Conrad C.; Conti A.; Dapavo P.; Ferreira P.; Gaiani F.; Leite L.; Malagoli P.; Mendes-Bastos P.; Megna M.; Messina F.; Nidegger A.; Odorici G.; Piaserico S.; Prignano F.; Ribero S.; Ricceri F.; Tonini A.; Valerio J.; Chiricozzi A.. - In: JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. - ISSN 0190-9622. - STAMPA. - 81:(2019), pp. 273-275. [10.1016/j.jaad.2019.02.031]
Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study
Prignano F.;
2019
Abstract
Secukinumab, an anti IL-17 monoclonal antibody, does represent a therapeutical choice for tthe treatment of moderate-sevre psoriasis. Drug survival of Secukinumab is not as low as initially reported . Our study ndicates that the durability of Secukinumab therapy in trating psoriasis patients in the real world setting, with relative lower drug survival in biologic-experienced obese patients.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
